Search | Clinical Trials Finder

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • West Palm Beach, Florida • Houston, Texas

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: HIV
Interventions: DV201P-RNA, DV202B1-RNA; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Boston, Massachusetts + 4 more

Conditions: HIV Infections
Interventions: VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: HIV Infections
Interventions: HIVAC-1e, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections, Pregnancy, HIV Seronegativity
Interventions: gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 2
States / cities: New Haven, Connecticut • Nashville, Tennessee

Conditions: HIV Infections
Interventions: HIV-1 Peptide Vaccine, Microparticulate Monovalent; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Baltimore, Maryland • Rochester, New York

Conditions: Monkeypox, Mpox, HIV
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Ad5.ENVA.48 HIV-1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 6 Months to 25 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 32
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 24 more

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Idiopathic CD4 T Cell Lymphocytopenia
Interventions: Gardasil 9; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Meningitis
Interventions: Quadrivalent meningococcal conjugate vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 35
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 25 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00, VRC-HIVADV014-00; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: JS7 DNA vaccine, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • San Francisco, California • Seattle, Washington

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 3
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 3
States / cities: San Francisco, California • Nashville, Tennessee • Seattle, Washington

Conditions: HIV Infections
Interventions: TBC-3B Vaccine, Smallpox Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 5
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 3 Days
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 36
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 23 more

Conditions: HIV Infections
Interventions: TUTI-16 (1.0 mg), Placebo; Biological · Other
Lead sponsor: Thymon, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

New York City Observational Study of Mpox Immunity

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

Early Immune Responses to Vaccination - A Substudy to HVTN 205

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)